Myelodysplastic syndromeNews & Research
14 curated articles for Myelodysplastic syndrome — FDA updates, peer-reviewed research, clinical-trial milestones, and sponsor press releases. Sorted newest-first.
- Annals of hematology Apr 21, 2026
Health-related quality of life of patients with acute myeloid leukemia and myelodysplastic syndromes/neoplasms treated with decitabine: a systematic literature review.
Decitabine, including its new oral formulation (decitabine-cedazuridine, DEC-C), is commonly used in AML and MDS, particularly in older or unfit patients. While its clinical efficacy and tolerability are well documented, evidence regarding patient-reported outcomes (PROs) and health-related quality ...
Why it matters: Recent peer-reviewed research on Myelodysplastic syndrome that may be relevant for patients and caregivers.
- Annals of hematology Apr 20, 2026
Very-low-dose decitabine and rhTPO for thrombocytopenia in lower-risk myelodysplastic syndrome.
Myelodysplastic syndrome (MDS) represents a heterogeneous group of myeloid neoplasms, with approximately two-thirds identified as lower-risk MDS (LR-MDS). LR-MDS with thrombocytopenia is associated with poor prognosis, a high risk of life-threatening hemorrhage, and limited treatment options. We exp...
Why it matters: Recent peer-reviewed research on Myelodysplastic syndrome that may be relevant for patients and caregivers.
- Journal of immunology (Baltimore, Md. : 1950) Apr 19, 2026
HIF-1α impairs NK cell differentiation-maturation and cytotoxicity in myelodysplastic syndrome via JAK1/STAT5/SOCS2 pathway.
Myelodysplastic syndrome (MDS) is a heterogeneous group of myeloid neoplasms characterized by treatment difficulties and a propensity to progress to acute myeloid leukemia. Impaired natural killer (NK) cell surveillance is a hallmark of MDS, yet the underlying molecular mechanisms remain poorly unde...
Why it matters: Recent peer-reviewed research on Myelodysplastic syndrome that may be relevant for patients and caregivers.
- Current hematologic malignancy reports Apr 17, 2026
Clonal Signatures of Telomere Biology Disorders.
In inherited bone marrow failure syndromes (IBMFS), clonal hematopoiesis (CH) has been increasingly recognized as a molecular fingerprint of the underlying pathophysiology. A specific clonal profile has been reported in telomere biology disorders (TBDs), an IBMFS caused by pathogenic germline varian...
Why it matters: Recent peer-reviewed research on Myelodysplastic syndrome that may be relevant for patients and caregivers.
- Haematologica Apr 1, 2026
TGFβ-activated kinase-1 knockdown in hematopoietic stem-progenitor cells causes PANoptosis and myelodysplastic syndrome-like disease in mice.
Mutant SF3B1 (SF3B1mut) in hematopoietic stem/progenitor cells (HSPC) primarily affects erythropoiesis, resulting in myelodysplastic syndromes (MDS) with refractory macrocytic anemia and ring sideroblasts. SF3B1mut results in aberrant splicing of a large number of transcripts in HSPC due to the alte...
Why it matters: Recent peer-reviewed research on Myelodysplastic syndrome that may be relevant for patients and caregivers.
- American journal of hematology Mar 17, 2026
Hematologic Landscape of Adult Patients With Diamond-Blackfan Anemia Syndrome.
Information about Diamond-Blackfan anemia syndrome (DBAS), a ribosomopathy associated with anemia, congenital anomalies and cancer predisposition is limited in adults. Using the French DBAS registry, 235 adult patients with DBAS were analyzed for hematological outcomes. At last follow-up, anemia, ne...
Why it matters: Recent peer-reviewed research on Myelodysplastic syndrome that may be relevant for patients and caregivers.
- British journal of haematology Mar 17, 2026
Safety and effectiveness of the combination of 5-azacitidine and ruxolitinib in VEXAS syndrome: A single-centre experience.
Safety and effectiveness of the combination of 5-azacitidine and ruxolitinib in VEXAS syndrome: A single-centre experience.
Why it matters: Recent peer-reviewed research on Myelodysplastic syndrome that may be relevant for patients and caregivers.
- Blood Mar 12, 2026
Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial.
To prevent graft-versus-host disease (GVHD) in patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation (alloHSCT), a calcineurin inhibitor plus methotrexate is routinely used. Early phase studies suggested improved outcomes with Orca-T, an allogeneic T-cell immunotherapy...
Why it matters: Recent peer-reviewed research on Myelodysplastic syndrome that may be relevant for patients and caregivers.
- International journal of hematology Mar 7, 2026
BRD9 depletion-mediated ALOX5 upregulation via chromatin dysregulation induces ferroptosis in SF3B1-mutant hematopoiesis.
SF3B1 mutations are among the most common splicing factor mutations in myeloid malignancies, yet the mechanisms linking aberrant splicing to metabolic phenotypes remain incompletely understood. We previously demonstrated that SF3B1 mutations cause nonsense-mediated decay of BRD9, a core component of...
Why it matters: Recent peer-reviewed research on Myelodysplastic syndrome that may be relevant for patients and caregivers.
- Bone marrow transplantation Mar 6, 2026
Therapy of high-risk myelodysplastic syndromes.
Higher-risk myelodysplastic syndrome (HR-MDS) is a heterogeneous group of hematopoietic malignancies primarily affecting the elderly, characterized by ineffective hematopoiesis, cytopenias, and a risk of transformation to acute myeloblastic leukemia. This review outlines the current landscape of HR-...
Why it matters: Recent peer-reviewed research on Myelodysplastic syndrome that may be relevant for patients and caregivers.
- Frontiers in immunology Feb 20, 2026
Myelodysplastic syndrome progress to acute myeloid leukemia: new insights and updates.
The progression of myelodysplastic syndromes (MDS) to secondary acute myeloid leukemia (sAML), classified under AML with myelodysplasia-related changes (AML-MRC), is a multi-step process driven by the dynamic interplay between cell-intrinsic genetic events and extrinsic microenvironmental remodeling...
Why it matters: Recent peer-reviewed research on Myelodysplastic syndrome that may be relevant for patients and caregivers.
- Pathology oncology research : POR Feb 18, 2026
Editorial: Cytometry in oncology.
Editorial: Cytometry in oncology.
Why it matters: Recent peer-reviewed research on Myelodysplastic syndrome that may be relevant for patients and caregivers.
- Surgical pathology clinics Feb 6, 2026
Beyond Sweet Syndrome: Untangling the Threads of Histiocytoid Sweet Syndrome and Cutaneous Myeloid Neoplasia.
Histiocytoid Sweet syndrome (H-SS) is a variant of Sweet syndrome characterized by an infiltrate of immature, "histiocytoid," myeloid cells. Myelodysplastic syndrome involving the skin (MDS cutis) and Vacuoles, E1-enzyme, X chromosome, Autoinflammation, Somatic (VEXAS) syndrome may clinically and hi...
Why it matters: Recent peer-reviewed research on Myelodysplastic syndrome that may be relevant for patients and caregivers.
- Current opinion in hematology Jan 29, 2026
Navigating prognostic stratification and approach to TP53 -mutated myeloid neoplasms.
TP53- mutated ( TP53 -MT) myeloid neoplasms (MN) represent one of the most challenging disease subsets due to their distinct pathobiology, frequent association with therapy-related disease, chemo-resistant phenotype, and dismal outcomes. The prognostic impact of TP53 -MT is not uniform and is influe...
Why it matters: Recent peer-reviewed research on Myelodysplastic syndrome that may be relevant for patients and caregivers.
More on Myelodysplastic syndrome
Articles aggregated from peer-reviewed journals (PubMed), sponsor press releases, SEC 8-K filings, and FDA announcements. Original-source links are preserved on each article page. Editorial tags (Breaking / Notable / Update) reflect UniteRare's curation-time priority assessment.